U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H28N2O3
Molecular Weight 368.4693
Optical Activity ( - )
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Zolunicant, (-)-

SMILES

[H][C@@]12[C@@H](CCOC)C[C@H]3C[N@@]1CCC4=C(NC5=CC=CC=C45)[C@@]2(C3)C(=O)OC

InChI

InChIKey=DTJQBBHYRQYDEG-SVBQBFEESA-N
InChI=1S/C22H28N2O3/c1-26-10-8-15-11-14-12-22(21(25)27-2)19-17(7-9-24(13-14)20(15)22)16-5-3-4-6-18(16)23-19/h3-6,14-15,20,23H,7-13H2,1-2H3/t14-,15+,20+,22-/m1/s1

HIDE SMILES / InChI
18-Methoxycoronaridine (18-MC) is a derivative of ibogaine invented in 1996 by the research team around the pharmacologist Stanley D. Glick from the Albany Medical College and the chemist Martin E. Kuehne from the University of Vermont. In animal studies it has proved to be effective at reducing self-administration of morphine, cocaine, methamphetamine, nicotine and sucrose. 18-MC is a α3β4 nicotinic antagonist and, in contrast to ibogaine, has no affinity at the α4β2 subtype nor at NMDA-channels nor at the serotonin transporter, and has significantly reduced affinity for sodium channels and for the σ receptor, but retains modest affinity for μ-opioid receptors where it acts as an antagonist, and κ-opioid receptors. The sites of action in the brain include the medial habenula, interpeduncular nucleus, dorsolateral tegmentum and basolateral amygdala. Unlike ibogaine and its principal metabolite noribogaine, 18-MC does not increase expression of glial cell line-derived neurotrophic factor (GDNF) in a dopaminergic–like cell line. 18-Methoxycoronaridine is a potent leishmanicide effect against Leishmania amazonensis, a causative agent of cutaneous and diffuse cutaneous leishmaniasis in the New World.

Approval Year

PubMed

PubMed

TitleDatePubMed
Time-dependent interactions between iboga agents and cocaine.
1997 Oct 8
Mechanisms of action of ibogaine: relevance to putative therapeutic effects and development of a safer iboga alkaloid congener.
2001
Modulation of nicotine self-administration in rats by combination therapy with agents blocking alpha 3 beta 4 nicotinic receptors.
2002 Jul 19
Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment.
2003 Jun
Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration.
2004 May 25
Subtypes of neuronal nicotinic acetylcholine receptors involved in nicotine-induced phosphorylation of extracellular signal-regulated protein kinase in PC12h cells.
2006 Jan 9
18-Methoxycoronaridine, a potential anti-obesity agent, does not produce a conditioned taste aversion in rats.
2010 Sep
Patents

Sample Use Guides

Rats: Pretreatment with 18-MC (20 mg/kg, i.p.), given prior to the administration of ghrelin (1 ug, lateral ventricle), blocked ghrelin-induced increases in sucrose (5%) intake in a two-bottle open access paradigm. Using in vivo microdialysis, 18-MC (both 20 and 40 mg/kg) prevented ghrelin (2 ug, intraventral tegmental area)-induced increases in extracellular dopamine in the nucleus accumbens.
Route of Administration: Intraperitoneal
In vitro studies have demonstrated that 18-MC is a potent antagonist of alpha3beta4 nicotinic receptors (IC50=0.75 uM), which are predominantly located in the medial habenula and interpeduncular nuclei.
Name Type Language
Zolunicant, (-)-
Common Name English
IBOGAMINE-18-CARBOXYLIC ACID, 21-METHOXY-, METHYL ESTER
Common Name English
18-METHOXYCORONARIDINE
Common Name English
(-)-18-METHOXYCORONARIDINE
Common Name English
Code System Code Type Description
PUBCHEM
15479177
Created by admin on Sat Dec 16 10:07:16 GMT 2023 , Edited by admin on Sat Dec 16 10:07:16 GMT 2023
PRIMARY
CAS
308123-60-6
Created by admin on Sat Dec 16 10:07:16 GMT 2023 , Edited by admin on Sat Dec 16 10:07:16 GMT 2023
PRIMARY
WIKIPEDIA
18-Methoxycoronaridine
Created by admin on Sat Dec 16 10:07:16 GMT 2023 , Edited by admin on Sat Dec 16 10:07:16 GMT 2023
PRIMARY
EPA CompTox
DTXSID40437331
Created by admin on Sat Dec 16 10:07:16 GMT 2023 , Edited by admin on Sat Dec 16 10:07:16 GMT 2023
PRIMARY
DRUG BANK
DB15096
Created by admin on Sat Dec 16 10:07:16 GMT 2023 , Edited by admin on Sat Dec 16 10:07:16 GMT 2023
PRIMARY
FDA UNII
KX8NQX91Z8
Created by admin on Sat Dec 16 10:07:16 GMT 2023 , Edited by admin on Sat Dec 16 10:07:16 GMT 2023
PRIMARY